ARQT - NASDAQ

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQTยทNASDAQ

$21.35

-0.56%
HealthcareBiotechnology

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.67B
EPS-0.1300
P/E Ratio-164.23
Earnings Date08/05/2026
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. Fair Value Envelope

ARQT ยท NASDAQ

Our analysis suggests that ARQT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.35, this represents a potential HIDDEN relative to our calculated worth for Arcutis Biotherapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $21.35

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$4.6B
+ Cash & Equivalents$42.9M
Firm Value-$4.6B
- Debt$6.3M
Equity Value-$4.6B
/ Shares Outstanding122,479,487B
DCF Value-$37
OVERVALUED BY 275%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$10.9M
-$21.3M
-$41.3M
-$80.3M
-$156.1M
-$303.4M
-$589.8M
-$1.1B
-$2.2B
-$4.3B
Maintenance CapEx
-$266.7K
-$518.4K
-$1.0M
-$2.0M
-$3.8M
-$7.4M
-$14.4M
-$28.0M
-$54.4M
-$105.7M
Owner Earnings
-$11.2M
-$21.8M
-$42.3M
-$82.3M
-$159.9M
-$310.8M
-$604.2M
-$1.2B
-$2.3B
-$4.4B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$10.4M
-$18.7M
-$33.6M
-$60.5M
-$108.8M
-$195.9M
-$352.5M
-$634.5M
-$1.1B
-$2.1B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ARQT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.